Loading...
Altimmune, Inc.
ALT•NASDAQ
Healthcare
Biotechnology
$3.61
$-4.10(-53.18%)
Altimmune, Inc. (ALT) Financial Performance & Statements
Review Altimmune, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns to understand its financial health and growth.
Revenue Growth
-95.31%
↓ 95.31%
Operating Income Growth
-7.55%
↓ 7.55%
Net Income Growth
-7.48%
↓ 7.48%
Operating Cash Flow Growth
-5.33%
↓ 5.33%
Operating Margin
-490965.00%
↓ 490965.00%
Gross Margin
-205.00%
↓ 205.00%
Net Profit Margin
-451200.00%
↓ 451200.00%
ROE
-65.44%
↓ 65.44%
ROIC
-66.59%
↓ 66.59%
Altimmune, Inc. (ALT) Financial Statements
Explore quarterly and annual reports including balance sheet, income statement, cash flow for Altimmune, Inc. stock.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $5000.00 | $5000.00 | $5000.00 | $5000.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $61000.00 |
| Gross Profit | $0.00 | -$28000.00 | $5000.00 | -$56000.00 |
| Gross Profit Ratio | $0.00 | -$5.60 | $1.00 | -$11.20 |
| R&D Expenses | $15.83M | $19.78M | $19.80M | $21.16M |
| SG&A Expenses | $5.99M | $5.09M | $4.97M | $5.59M |
| Operating Expenses | $21.82M | $24.87M | $24.77M | $26.75M |
| Total Costs & Expenses | $0.00 | $24.83M | $24.77M | $26.75M |
| Interest Income | $1.54M | $1.57M | $1.91M | $2.18M |
| Interest Expense | -$1000.00 | $1000.00 | $6000.00 | $1000.00 |
| Depreciation & Amortization | $0.00 | $33000.00 | $37000.00 | $61000.00 |
| EBITDA | -$21.82M | -$23.15M | -$22.80M | -$24.58M |
| EBITDA Ratio | -$4363.00 | -$4629.20 | -$4560.40 | -$4915.60 |
| Operating Income | -$21.82M | -$24.87M | -$24.77M | -$26.75M |
| Operating Income Ratio | -$4363.00 | -$4973.20 | -$4953.40 | -$5349.00 |
| Other Income/Expenses (Net) | $1.56M | $1.69M | $1.92M | $2.10M |
| Income Before Tax | -$20.26M | -$23.18M | -$22.84M | -$24.64M |
| Income Before Tax Ratio | -$4051.20 | -$4636.00 | -$4569.00 | -$4928.00 |
| Income Tax Expense | -$681000.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$19.57M | -$23.18M | -$22.84M | -$24.64M |
| Net Income Ratio | -$3915.00 | -$4636.00 | -$4569.00 | -$4928.00 |
| EPS | -$0.26 | -$0.33 | -$0.32 | -$0.35 |
| Diluted EPS | -$0.26 | -$0.33 | -$0.32 | -$0.35 |
| Weighted Avg Shares Outstanding | $75.55M | $71.26M | $71.08M | $70.92M |
| Weighted Avg Shares Outstanding (Diluted) | $75.55M | $71.26M | $71.08M | $70.92M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan